The results of MADIT-CRT suggest patients with early stage (NYHA class I/II) symptomatic heart failure (HF) indicated for an implantable cardioverter defibrillator (ICD) may benefit from the addition of cardiac resynchronization therapy (CRT). How likely are these results to increase device implant rates? Take our poll and see how your colleagues responded.

How do you think the results of the MADIT-CRT trial (and other studies suggesting benefits of CRT device-based therapy in earlier-stage HF patients) will affect implant CRT rates in the next 3 years?
See: MADIT-CRT: Resynchronization therapy cuts heart-failure risk in patients with only mild disease

	Rates will significantly increase (> 15% increase in primary prevention ICD utilization in congestive HF patients)
	Rates will moderately increase (5%-10%)
	Rates will slightly increase (2%-5%)
	Rates will slightly increase (2%-5%)